Quick Dispatch:
Your hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) ships.
Need Help?
Questions about hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301), sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp 1 China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301) in your area.
Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial
26.31
Oral GLP-1 Market to Rise at 35.05% CAGR till 2035
29.90
Hefty $6 Billion Deal: Hengrui Licenses GLP-1 Portfolio to Hercules
23.64
GLP-1 Agonists Market Report 2025-2033, By Product, Molecule, and Geo
29.40
Ribupatide, An Oral Dual GLP-1/GIP, Achieves Weight Loss in Phase 2 Obesity Trial
25.17
Hengrui Leads Oral GLP-1, Shanghai New Cell Therapy Policy: China biotech Weekly Roundup
27.57
BMS signs $15.2bn R&D alliance with China's Hengrui
28.18
